Wells Fargo raised the firm’s price target on Mineralys Therapeutics (MLYS) to $50 from $26 and keeps an Overweight rating on the shares, reflecting increased probability in hypertension and confidence in competitive positioning. The firm sees the investment thesis revolving more around the M&A case over the next few quarters.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
- Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position
- Mineralys announces new subgroup analyses from Phase 3 Launch-HTN trial
- Mineralys Therapeutics Announces Public Offering of Shares
- Mineralys Therapeutics 9.8M share Spot Secondary priced at $25.50